Reversible Left Ventricular Systolic Dysfunction Secondary to Pazopanib. 2018

Kushani Gajjar, and Kathir Balakumaran, and Agnes S Kim
Internal Medicine, University of Connecticut Health Center, Farmington, USA.

Pazopanib is a tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. We describe a case report of a patient with spindle cell sarcoma who developed severe left ventricular systolic dysfunction after starting pazopanib therapy with subsequent recovery of left ventricular ejection fraction upon stopping therapy.

UI MeSH Term Description Entries

Related Publications

Kushani Gajjar, and Kathir Balakumaran, and Agnes S Kim
May 2007, The Canadian journal of cardiology,
Kushani Gajjar, and Kathir Balakumaran, and Agnes S Kim
August 1993, International journal of cardiology,
Kushani Gajjar, and Kathir Balakumaran, and Agnes S Kim
May 2001, Japanese heart journal,
Kushani Gajjar, and Kathir Balakumaran, and Agnes S Kim
May 2015, BMJ case reports,
Kushani Gajjar, and Kathir Balakumaran, and Agnes S Kim
July 2000, Echocardiography (Mount Kisco, N.Y.),
Kushani Gajjar, and Kathir Balakumaran, and Agnes S Kim
December 2008, Current heart failure reports,
Kushani Gajjar, and Kathir Balakumaran, and Agnes S Kim
January 1997, Duodecim; laaketieteellinen aikakauskirja,
Kushani Gajjar, and Kathir Balakumaran, and Agnes S Kim
January 2004, Reviews in cardiovascular medicine,
Kushani Gajjar, and Kathir Balakumaran, and Agnes S Kim
October 2002, European journal of heart failure,
Kushani Gajjar, and Kathir Balakumaran, and Agnes S Kim
September 1996, The Nurse practitioner,
Copied contents to your clipboard!